Dialectic Therapeutics, Inc.

Dialectic Therapeutics Initiates Phase 1b/2 Trial of DT2216 in Platinum-Resistant Ovarian Cancer

- Dialectic Therapeutics has begun dosing the first patients in a Phase 1b/2 clinical trial testing DT2216 combined with paclitaxel for platinum-resistant ovarian cancer at Dana-Farber Cancer Institute. - The novel BCL-XL protein degrader DT2216 demonstrated complete tumor eradication in preclinical ovarian cancer models, including highly chemotherapy-resistant patient-derived xenografts. - The Phase 1a trial of DT2216 established a recommended Phase 2 dose with favorable safety profile and confirmed target engagement in all patients at the therapeutic dose level. - The combination therapy addresses a critical unmet medical need in platinum-resistant ovarian cancer, where new therapeutic options are urgently needed for patients.